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all-cause mortality (RR: 0.89, 95% CI: 0.76 – 1.04, P ¼ 0.979) between
AT and PPCI arm at 1-month (RR: 0.89, 95% CI: 0.76 – 1.04, P ¼ 0.155),
6-12 months (RR: 0.87, 95% CI: 0.38 – 1.98, P ¼ 0.620) and >12 months
(RR: 0.73, 95% CI: 0.49 – 1.09, P ¼ 0.12) follow-up. The 2 groups were
similar with regards to target vessel revascularization (RR: 0.79, 95%
CI: 0.60 – 1.04, P ¼ 0.149) and stroke (RR: 1.45, 95% CI: 0.84 – 2.50, P ¼
0.620) however there was a signiﬁcant reduction of recurrent MI (RR:
0.67, 95% CI: 0.46 – 0.97, P ¼ 0.032) and MACE (Death þ MI þ target
vessel revascularization) rate (RR: 0.81, 95% CI: 0.66 – 0.99, P ¼ 0.031)
in AT arm when compared to PPCI. The net clinical beneﬁt (MACE þ
stroke) was similar in the two groups (RR: 0.97, 95% CI: 0.87 – 1.07, P ¼
0.710).
CONCLUSIONS In this largest till date meta-analysis, including all the
available randomized controlled trial ,we show that AT prior to PPCI in
STEMI is associated with similar mortality, stroke and target revas-
cularization rates however there is a signiﬁcant reduction of MACE
rate in the AT arm primarily driven by reduced rates of recurrent MI.
There was no difference between the two treatment arms in terms of
net clinical beneﬁt.
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BACKGROUND Previous evaluations of endovascular cooling during
primary PCI for acute myocardial infarction (MI) in human and animal
studies suggest a treatment effect on infarct size (IS) related to core
temperature at the time of reperfusion. These observations have not
translated into results of recent randomized trials. We investigated a
comparative dose response relationship between myocardial salvage
and depth of cooling.
METHODS Twenty-four pigs were randomly assigned to 3 groups:
normothermia 38C, mild hypothermia 35C and moderate hypother-
mia 32C. MI was induced by 1-hour balloon occlusion of the mid LAD
followed by reperfusion. A heat-exchange balloon catheter placed in
the inferior vena cava controlled core temperature. Cooling was
initiated 30 minutes after occlusion and maintained for 1 hour fol-
lowed by rewarming to normothermia. IS was assessed at day 6 with
magnetic resonance imaging (CMR) and pathology (TTC).
RESULTS Target temperature was reached in 95 and 298 minutes
for 35C and 32C, respectively. Area-at-risk (AAR) from TTC staining
was equivalent in all groups (306, 287, 266, ANOVA p¼0.217).
Both the 32C and 35C showed signiﬁcant IS reduction per AAR
(4512, 1711, 43, 62% and 91% reduction, respectively, p<0.001)
and a similar reduction per LV mass (145, 53, 11, p<0.001).
Further, 32C showed a signiﬁcant 76% IS per AAR reduction relative
to 35C (p¼0.013) suggesting additional tissue salvage from deeper
cooling. In the linear regression model, target temperature was a
signiﬁcant predictor of IS reduction both per AAR and LV (R2¼ 0.746
and 0.685, respectively, p<0.001). The predicted infarct reduction is
7% of AAR and 2% of LV per 1C drop at reperfusion. Additionally, 32C
had less variability compared to 35C in reducing IS (standard devia-
tion 3 vs 10 relative to AAR and 1 vs 3 relative to LV). In-vivo CMR
imaging evaluation also supported results of signiﬁcant IS reduction
with 32C (104*, 83, 32*, *p<0.001). Cardiac output relative to
baseline was signiﬁcantly preserved in 32C only (-30%19*, -17%32,
-1%28*, *p¼0.041). Both 35C and 32C exhibited signiﬁcant re-
ductions in T2 edema suggesting reduced injury with hypothermia
(p<0.05).CONCLUSIONS Pre-reperfusion rapid therapeutic hypothermia shows
a dose-response infarct size reduction as well as favorable hemody-
namic outcomes for moderate hypothermia more consistently than
mild hypothermia.
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BACKGROUND State-of-art therapeutics for acute myocardial infarc-
tion (AMI) have dramatically improved clinical outcome during the
ﬁrst year after index AMI. However, few data exist on the remnant risk
of recurrent cardiovascular (CV) events in the stable post-MI 1-year
survivors.
METHODS We consecutively enrolled AMI patients who underwent
percutaneous coronary intervention (PCI) in the COREA-AMI (Car-
diOvascular Risk and idEntiﬁcAtion of potential high-risk population
in AMI) registry including nine major university hospitals throughout
South Korea from January 2004 to December 2009. Patients who were
alive and did not experience a recurrent MI or stroke during the ﬁrst
365 days post-index MI were analyzed in this study. We deﬁned “high
risk” as patients with at least one of the following risk factors: age 65
years, diabetes mellitus, prior MI, multi-vessel disease, or renal
dysfunction. The primary endpoint was a composite of CV death, non-
fatal MI, or stroke from Day 366 to study completion.
RESULTS Of 4,748 AMI patients, 4,200 patients were alive at 1 year
after index MI stably without non-fatal MI, or stroke. Median follow-
up duration was 43.8 months (interquartile range 29.8 to 60.5
months). Within the ﬁrst year, combined endpoints of CV events
were 3.0% at low risk and 8.4% at high risk [HR (95%CI) 2.87 (1.91-
4.31), p<0.001]. From 1 year to 4 year after index MI, cumulative
incidence of CV events were 3.9% at low risk and 8.8% at high
risk [2.25 (1.49-3.40), p<0.001]. In multivariable Cox proportional
regression analysis, additional risk factors of stable post-MI patients
were left ventricular dysfunction [1.50 (1.15-1.95), p¼0.002] and
anemia [1.40 (1.08-1.83), p¼0.011]. Patients without taking dual
antiplatelet agent at 1 year have borderline remnant risk [1.31
(0.99-1.73), p¼0.059].
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even in the stable post-MI 1-year survivors who received current state-
of-art therapeutics. Further larger studies are needed to deﬁne the
high-risk group in Korean stable post-MI survivors.
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BACKGROUND Current guidelines recommend appropriate revascu-
larization and optimal medical treatment (OMT) including antiplatelet
therapy, statin, beta-blocker, or renin-angiotensin system (RAS)
blocker in the treatment of acute myocardial infarction (AMI). The
purpose of this study is to describe the prescription status for OMT
and long-term clinical outcome according to the status for OMT at
discharge and at 1-year.
METHODS We consecutively enrolled AMI patients who underwent
percutaneous coronary intervention (PCI) in the COREA-AMI (CardiOvas-
cular Risk and idEntiﬁcAtion of potential high-risk population in AMI)
registry including nine major university hospitals throughout South Korea
from January 2004 to December 2009. OMTwas deﬁned as taking all three
medications including statin, beta-blocker, and RAS blocker (angiotensin
converting enzyme inhibitor or angiotensin receptor blocker) with dual
antiplatelet agent (DAPT) at discharge or with one or more antiplatelet
agent at 1 year. The primary endpoint was all-cause death and landmark
analysis for 1-year post-MI survivors were performed.
RESULTS Of 4,748 AMI patients, 2,517 were taking OMT with DAPT and
1,878 were not taking OMT at discharge. At 1 year, 1,719 were prescribed
OMT with one or more antiplatelet 1,845 were not prescribed OMT among
4,200whowere aliveat 1 year stablywithoutnon-fatalMIor stroke.Median
follow-up duration was 43.8 months (interquartile range 29.8 to 60.5
months).Within theﬁrst year, the incidence ratesofprimaryendpointwere
2.3% in OMT group and 5.4% in non-OMT group [Unadjusted HR (95%CI)
2.32 (1.69-3.19), p<0.001]. After 1 year from index PCI, all-cause deathwere
5.6% inOMTgroup and9.8% innon-OMTgroup [1.92 (1.43-2.59), p<0.001].
In multivariable Cox proportional hazards regression, non-OMT was inde-
pendent predictor for the primary endpointswithin the ﬁrst year [AdjustedHR 1.85 (1.34-2.57), p<0.001] and after 1 year from index AMI year [1.54
(1.14-2.09), p¼0.005]
CONCLUSIONS About 40% of post MI survivors were not prescribed
full OMT at the time of discharge or at 1 year. Long-term clinical
outcome was signiﬁcantly superior in the OMT group as compared
with non-OMT group not only within the ﬁrst year but also from 1 year
to study completion among stable post-MI 1 year survivors.
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BACKGROUND Clinical trials have failed to show a clear beneﬁt of
mechanical unloading of the left ventricle (LV) to limit ischemia-
reperfusion injury (IRI) in acute myocardial infarction (AMI), which
may reﬂect a poor understanding of whether to unload the LV before
or after reperfusion. We explored the kinetics of LV unloading with an
axial ﬂow catheter (Impella) in relation to balloon reperfusion as a
strategy to reduce infarct size and improve survival in AMI.
METHODS Weﬁrst employed a swinemodel of AMI. After 90minutes of
LAD occlusion, adult, male swine (n¼4.group) were randomized to
either: 1) 120 minutes of reperfusion alone (IRI), 2) 15, 30, or 60 minutes
of LV unloading before 120minutes of coronary reperfusion (Impella to
Balloon Group; ITB-15; ITB-30; ITB-60) or 3) 30 minutes of coronary
reperfusion followed by LV unloading and an additional 120 minutes of
reperfusion (Balloon to Impella Group; BTI-30). Infarct size,myocardial
kinase activity, and mitochondrial integrity were quantiﬁed. To begin
exploring the clinical utility of LV unloading before reperfusion we
retrospectively studied all patients in the USPella registry presenting
with acute ST-segment elevationmyocardial infarction and cardiogenic
shock who received an Impella within 120 minutes before (n¼41;
STEMI-ITB) or within 120 minutes after (n¼76; STEMI-BTI) percuta-
neous coronary reperfusion between 2009 and 2014.
RESULTS Compared to IRI alone, infarct size was reduced in the ITB-30
and ITB-60 groups, but not in the ITB-15 or BTI groups (Figure). Levels of
phosphorylated Akt, Erk-1/2, GSK3b and mitochondria per cardiomyocyte
were increasedwithin the infarct zone in the ITB-30and ITB-60groups, not
theBTI group. In the registry analysis, in-hospital (51%vs 28%,p¼0.02) and
30-day survival (42% vs 20%, p¼0.03) were higher in the STEMI-ITB than
the STEMI-BTI group.ASTEMI-ITB timeof less than60minutes (n¼38)was
associated with higher in-hospital survival than a STEMI-BTI time of less
than 60 minutes (n¼40) (50% vs 25%, p¼0.02).
